Emerging evidence has linked MRI signal changes in deep nuclei of the brain with repeated
administration of gadolinium-based contrast agents. Gadolinium deposits have been …

In the past 4 years, many publications described a concentration-dependent deposition of
gadolinium in the brain both in adults and children, seen as high signal intensities in the …

Objective The purpose of this study was to determine whether gadolinium (Gd) is deposited
in brain and bone tissues in patients receiving only non–Group 1 agents, either macrocyclic …

Purpose To determine whether gadolinium deposits in neural tissues of patients with
intracranial abnormalities following intravenous gadolinium-based contrast agent (GBCA) …

Gadolinium-based contrast agents (GBCAs) have an excellent safety profile. However, over
the last 2 decades, two specific concerns have surfaced. GBCAs are associated with …

Gadolinium-based contrast agents (GBCAs) are commonly used for enhancement in MR
imaging and have long been considered safe when administered at recommended doses …

Objectives To compare the diagnostic performance of contrast-enhanced spectral
mammography (CESM) to digital mammography (MG) and magnetic resonance imaging …

Gadolinium-based contrast agents (GBCAs) have transformed magnetic resonance imaging
(MRI) by facilitating the use of contrast-enhanced MRI to allow vital clinical diagnosis in a …

Purpose To compare gadolinium tissue concentrations of multiple linear and macrocyclic
chelates in a rat model to better understand the scope and extent of tissue deposition …

Objective Multiple clinical and preclinical studies have reported a signal intensity increase
and the presence of gadolinium (Gd) in the brain after repeated administration of Gd-based …